Sequenom nearly doubles Q2 sales; Quest teams up with the NFL's Giants;

@FierceMedDev: Boston Scientific's Q2 reflects both stagnation and promising growth. Article | Follow @FierceMedDev

@MarkHFierce: We are entering our last week for FMD F15 nominations. Get yours in now. Submission form | Follow @MarkHFierce

@DamianFierce: Roche posted only slight diagnostics growth in H1, as a diabetes slump weighed down testing sales. Story | Follow @DamianFierce

 @MichaelGFierce: From FierceDrugDelivery.com: Novaliq secures CE mark for OTC drop to treat dry eye. Report | Follow @MichaelGFierce

> Boston Scientific ($BSX) won FDA clearance for its Rhythmia cardiac mapping system, part of the company's efforts to expand in electrophysiology. Story

> Varian Medical ($VAR) posted $726 million in sales last quarter, a 3% increase over the same period last year. Results

> Sequenom ($SQNM) boosted sales by 91% in the second quarter, bringing in $34.9 million from its non-invasive prenatal tests. More

> Dialysis outfit NxStage Medical ($NXTM) recorded $65.5 million in sales last quarter, an 11% jump over the previous year, and the company reduced its net loss from $5.1 million to $3.4 million. Item

> Meridian Bioscience landed $47.1 million in sales last quarter, 12% above the same period last year. News

> While Quest Diagnostics ($DGX) is struggling with reimbursement cutbacks and declining revenue, the company found enough cash to sponsor the New York Giants' East Rutherford, NJ, practice facility. Article

Biotech News

@FierceBiotech: ICYMI: Sanofi returns to the crowdsourcing well for diabetes app. Article | Follow @FierceBiotech

@RyanMFierce: Stem cell pioneer's biotech startup raises $46M in IPO. Report | Follow @RyanMFierce

@EmilyMFierce: Inovio Pharma DNA cancer vaccine causes tumor death in animals. Article | Follow @EmilyMFierce

> AstraZeneca, Bristol resubmit NDA for diabetes therapy dapagliflozin. Report

> Johnson & Johnson, Vertex execs speak up for 'breakthrough' status in Washington. Article

> Teva, Lonza end biosimilars joint venture as the copycat crowd thins. News

> Industry Voices: mRNA-Based Therapies--Blueprints for Therapeutics. Feature

Pharma News

@FiercePharma: FTC eyeing new patent deals for pay-for-delay action in wake of SCOTUS ruling. ICYMI yesterday | Follow @FiercePharma

@CarlyHFierce: Wednesday at Fierce, starring Neuron, Measles, Tuberculosis, MRSA and E. coli. Image | Follow @CarlyHFierce

> GlaxoSmithKline to pay states $229M to wrap Avandia suits, other claims. Article

> Roche's 'blowout' cancer launches help fuel 10% profits hike. More

> Biogen's Tecfidera races past estimates with $192M in Q2 sales. Report

Pharma Manufacturing News

@EricPFierce: CMO Exela looks to get $1 million USDA loan to help expand plant, add jobs. Story | Follow @EricPFierce

> Fresenius Kabi Indian plant accused of manipulating data. More

> Lonza phasing out troubled Massachusetts biologics plant. Report

> FMC spends $345M for Epax omega-3 plants. Item

> FDA excoriates Wockhardt over missing records, standing urine. Story

> GSK looks to manufacturing to reduce vaccine costs. Article

Vaccines News

> Indian ethics journal pushes for ban on Crucell vaccine. Item

> Serum targets Merck, Sanofi stronghold with TB vax deal. More

> U.K. rejection of Bexsero hits Novartis vaccine unit. Report

> Lupin eyes vaccine growth after in-licensing Merck shot. News

> GSK planning joint venture to tap into Chinese vaccine demand. Article

> Study suggests GSK's Cervarix can prevent throat cancer. Story

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.